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Risk of human papillomavirus (HPV) transmission 
during laser vaporisation of genital warts or loop elec-
trode excision procedure is controversial. An oral rinse, 
a nasal swabs, history of HPV-related diseases and data 
on HPV exposure were collected from 287 employees at 
departments of dermato-venerology and gynaecology 
in Denmark. A mucosal HPV type was found among 
5.8% of employees with experience of laser treatment 
of genital warts as compared to 1.7% of those with no 
experience (p = 0.12). HPV prevalence was not higher in 
employees participating in electrosurgical treatment or 
cryotherapy of genital warts, or loop electrode excision 
procedure compared with those who did not. HPV 6 or 
11 were not detected in any samples. Hand warts after 
the age of 24 years was more common among dermato-
logy than among non-dermatology personnel (18% vs. 
8.0%, p = 0.03). Mucosal HPV types are infrequent in the 
oral and nasal cavity of health care personnel, however, 
employees at departments of dermato-venereology are 
at risk of acquiring hand warts. Key words: human pa-
pillomavirus; HPV; plume; LEEP; carbon dioxide laser; 
genital warts; condyloma acuminatum; hand warts. 
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Genital warts are caused by human papillomavirus 
(HPV), which is the most common sexually transmitted 
infection (STI) (1–3). At least 40 HPV types can infect 
the genital mucosa (4) and they are classified as oncoge-
nic (high-risk) or non-oncogenic (low-risk) HPV types, 
on the basis of their association with malignant genital 
lesions (5). The majority of genital warts is caused by 
the low-risk HPV types 6 or 11 (6, 7). Molecular and 
epidemiological studies have demonstrated the role of 
genital high-risk HPV, in the aetiology of oro-pharyngeal 
cancers (8, 9) and HPV types 6 and 11 is the cause of 
both juvenile- and adult-onset laryngeal papillomas (10). 
Genital HPV infections mainly spread by direct genital 
contact, especially in areas of epidermal barrier erosion 
or friction (11). Other routes of HPV transmission are 
incompletely understood. Oral HPV infection may be re-
lated to orogenital or oral-to-oral spread in adults (12, 13).
Occupational HPV transmission from patient to medi-
cal personnel during carbon dioxide (CO2) laser vaporisa-
tion of genital warts or loop electrode excision procedure 
(LEEP) of cervical dysplasia is controversial. Studies 
have shown that HPV DNA is present in the plume ge-
nerated during laser vaporisation of verrucae, laryngeal 
papillomas and genital warts (14–16). HPV 16 is the most 
frequently isolated HPV type from plume samples taken 
during LEEP (17). Two cases of laryngeal papillomatosis 
among operating personnel who used laser vaporisa-
tion to treat genital warts have been described (18, 19). 
This has resulted in increased use of personal protective 
equipment and smoke evacuators in Denmark during the 
last decade; which may be sufficient to protect medical 
personnel from acquiring HPV infection (20, 21). 
To investigate the prevalence of mucosal HPV types 
in the nasal and oral cavity and history of HPV-related 
diseases in relation to work exposures, we collected 
oral rinses, nasal swabs and information on HPV rela-
ted diseases from medical personnel at departments of 
gynaecology and dermato-venereology in Denmark. 
Results from the same cohort have been published in a 
previous paper (22). That paper focus on the presence 
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of HPV types from the Betapapillomavirus and Gamma-
papillomavirus genera in the nasal mucosa and does not 
contain results regarding the work-related exposition to 
HPV, work place or history of HPV-related diseases. 
METHODS
Participants
Medical personnel employed at departments of gynaecology 
and dermato-venereology was invited to participate. The par-
ticipating departments of dermato-venereology were located 
at Copenhagen University Hospital Gentofte and Bispebjerg, 
Odense University Hospital, and Aarhus University Hospital. 
The participating departments of gynaecology were located at 
Copenhagen University Hospital Hvidovre, Herlev and Hil-
leroed, Odense University Hospital, and Aarhus University 
Hospital. The total number of medical personnel at the par-
ticipating departments of dermatology is approximately 290, 
and approximately 1,320 medical personnel are working at the 
participating departments of gynaecology. The number of em-
ployees with experience of treating patients with HPV-related 
diseases is not known. Additionally, employees at a department 
at the medical faculty at Copenhagen University were invited to 
participate. The study was performed between 2010 and 2011. 
Participants had to be at least 18 years of age and should not 
have treated patients with HPV-related diseases for 24 h before 
sampling. The Scientific Ethical Committee of the Capital 
Region approved sample collection based on written informed 
consent (H-D-2010-077). All patients were offered access to 
their study results and subsequent counselling if needed.
After sampling the participants answered a questionnaire con-
cerning demographic data, previous and current work-related 
HPV exposure, and history of HPV-related diseases.
Sample collection
An oral rinse was obtained by means of a ≈30 s oral rinse and 
gargle with 7 ml isotonic saline collected in a 10 ml tube. Nasal 
samples were collected using a swab applicator with a nylon 
fibre flocked tip moistened in isotonic saline. The applicator 
was placed ≈1 cm inside the nostril, and with moderate pressure 
against the nasal septum rotated 3 times in each nostril. Sub-
sequently the applicator was placed in a cryo tube containing 
1.5 ml isotonic saline solution.
Analysis
After purification and amplification a Luminex-based HPV 
genotyping was used to identify HPV types as previously des-
cribed (7, 23). The technique allows the detection of at least 39 
HPV genotypes of which 15 are high-risk HPV genotypes: 16, 
18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82; and 5 
probable high-risk types genotypes: 26, 53, 66, 67 and 69, and 
19 low-risk HPV genotypes: 6, 11, 30, 40, 42, 43, 54, 61, 62, 
70, 74, 81, 83, 86, 87, 89, 90, 91 and 114. The Luminex assay 
also included 2 “universal” HPV probes and samples positive 
only for the “universal” probe were typed by DNA-sequencing. 
β-globin real-time PCR was included as a separate test of sample 
adequacy for PCR (7). Only participants with β-globin positive 
samples were included in the analysis. 
Statistics
Qualitative variables were given as number (percentage) and were 
studied using fisher’s exact test. Quantitative data were expressed 
as mean (± standard deviation) or median (range) as appropriate. 
Data analysis was conducted using SAS statistical software 
(SAS Institute Inc., Cary, NC, USA) and GraphPad Prism 
(GraphPad Software Inc., San Diego, CA, USA). p-values 
< 0.05 were considered to be statistically significant.
RESULTS
A total of 314 persons participated. Two did not fill out 
the questionnaire and were excluded and 25 participants 
from the medical faculty were excluded because they 
had not worked at a department of dermato-venereology 
or gynaecology. Characteristics of the 287 persons are 
given in Table SI1. As shown in Table SII1 there was no 
difference in the history of HPV-related diseases, warts 
since the age of 25 years or warts at inclusion between 
physicians and non-physicians. Participation in CO2 
laser treatment of HPV-related diseases did not influence 
the reported history of HPV-related diseases. A signifi-
cantly higher number of employees at a department of 
dermato-venerology reported having had an HPV related 
disease in their lifetime (OR 1.9; 95CI% 1.1-3.2).This 
was  mainly due to significantly employees reporting 
hand warts after the age of 24 years (OR 2.2; 95%CI 
1.1-4.5). Three persons, all of whom were employees at 
a department of dermato-venereology reported nasal or 
oro-pharyngeal warts after the age of 24 years. 
Due to a β-globin negative oral rinse or a nasal swab 
16 persons were not included in the analysis of oral or 
nasal HPV. HPV was isolated from 13 persons, types 
and sites are given in Table SIII1. The HPV type isolated 
from 2 participants was not regarded as a mucosal HPV 
type (HPV 10 and a putative subtype of a Gammapa-
pillomavirus HPV isolate) and thus not included in the 
comparative analysis. 
A mucosal HPV type was found among 5.8% of em-
ployees with experience of laser treatment of genital 
warts as compared to 1.7% of those with no experience 
(p = 0.12) (Table I). HPV 6 or 11 were not detected in 
any of the samples, while HPV 16 or 18 were found in 4. 
Employees participating in CO2 laser treatment of 
genital warts, had been doing the procedure for a median 
of 5 years (range 0–25). Laser personnel that treated 
patients with genital warts for at least 5 years had a 
significantly higher prevalence of mucosal HPV types 
in the nasal or oral cavity than employees that used 
CO2 laser for less than 5 years or never (OR 6.7 (95% 
CI 1.7–26.0; p = 0.004)). The median age of employees 
with ≥ 5 years experience of CO2 laser treatment was 49 
years (range 36–68), while the median age of personnel 
with less than 5 years or no experience of laser treat-
ment was 40 years (range 22–64). Persons performing 
cryotherapy or LEEP did not have a higher prevalence 
of mucosal HPV compared with those who did not. The 
prevalence of mucosal HPV was not significantly higher 
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1912
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in employees participating in electrosurgical treatment 
of genital warts (Table I).
All persons currently involved in CO2 laser treatment, 
reported taking some protective measures against HPV 
infection. All except 2 (93%) used examination gloves, 
88% used smoke evacuators and 79% laser plume 
masks. The majority (64%) of medical personnel who 
stopped using CO2 laser in the treatment of genital 
warts ≥ 5 years before the study was conducted took 
no protective measures against HPV infection or wore 
only examination gloves.
DISCUSSION 
In our study we found that participating in cryotherapy, 
CO2 laser or electrosurgical evaporation of genital 
warts or LEEP of cervical dysplasia did not signifi-
cantly increase the prevalence of nasal or oral HPV. 
In a recent study of medical personnel treating laryng-
eal papillomas and urethral warts using CO2 laser it was 
found that after treatment of urethral warts, HPV DNA 
corresponding to patient tissue specimens was present in 
all samples obtained from the gloves of the surgeons (21). 
Oral mucosa samples from all 18 different employees 
tested HPV negative, as did the surgical mask specimens. 
Similar results have been found by others (20, 24). Thus, 
it seems that wearing a laser plume mask or even a sur-
gical mask protects from upper airway HPV infection. 
Or it may be that regardless of protective measures the 
risk of HPV infection by inhalation of laser plume is 
very small. Bellina et al. (24) showed that only a few 
morphologically intact cells are present in the plume 
collected during CO2 laser treatment of genital warts and 
incubation of the cellular debris resulted in no metabolic 
activity, replication or transcription of HPV. On the other 
hand, Garden et al. (25) treated bovine papillomavirus 
(BPV)-induced cutaneous fibropapillomas on calves with 
CO2 laser. The laser plume was collected and then re-
inoculated onto the skin of other calves. fibropapillomas 
developed at laser plume-inoculated sites. 
We did not detect HPV 6 or 11, which is by far 
most frequently encountered types in genital warts, 
in a single employee (6, 7). However, we did find an 
elevated prevalence of nasal or oral HPV in employees 
that had participated in CO2 laser for at least 5 years. 
This may simply be due to an increasing number of 
nasopharyngeal HPV infections with age, which have 
previously been shown (13, 26). Only 13 (4.4%) em-
ployees had a mucosal HPV positive sample. In another 
study collected oral mucosa specimens from 18 health 
care professionals all tested HPV negative (21). The 
reported prevalence of HPV in oral rinse samples in 
the United States among men and women aged 14–69 
years is 6.9% (13). In that study the prevalence of HPV 
16 and 18 were 1% and 0.25%, respectively, which is 
approximately the same as detected in our study. A si-
milarly low prevalence of high-risk HPV types (0.63%) 
was found in mouthwash from Swedish healthy controls 
(27). However, among normal oral cavity scrapings 
taken with a brush Rautava et al. (28), reported HPV 
DNA prevalence of 17% in finnish pregnant women.
We found that employees at a department of dermato-
venerology have a greater prevalence of hand warts 
and possibly nasal or oral warts, than employees at 
departments of gynaecology. In a study based on a self-
administered questionnaire, 4 out of 570 U.S. CO2 laser 
surgeons reported a history with nasopharyngeal warts. 
This small number was significantly higher than the num-
ber observed in matched control subjects (29). However, 
when warts were grouped together without specification 
of anatomic site the reported prevalence of warts among 
the laser surgeons was not significantly different from 
the prevalence in the control group (29). Lobraico et al. 
(30) conducted a survey by a question naire sent to laser 
users, and discovered a significantly higher prevalence of 
acquired hand warts among the dermatologists compared 
to other specialties. However, genital warts and warts of 
the skin are induced by an entirely different set of HPV. 
Our study has some limitations. Detection of HPV is 
dependent on sampling procedure and assay sensitivity 
and specificity. In the assay and sampling procedures 
we used may not have been able to detected low pro-
ductive infections e.g. in the tonsillar crypts. When 
asked in hindsight every specialised health care profes-
sional may have a stronger recall of diseases, which 
belong to their own area of experience than the ones 
that do not. Even though this study is by far the largest 
on the prevalence of nasopharyngeal HPV in medical 
personnel it might still be too small to detect important 
Table I. Mucosal human papillomavirus type in relation to exposure
Work exposure and position
HPV+ 
n (%)
HPV– 
n pa
Treating human papillomavirus (HPV) related diseases
Yes 11 (4.9) 213
No 0 (0.0) 47 0.22
CO2-laser treatment of genital warts
Yes 9 (5.8) 147
No 2 (1.7) 113 0.12
Cryotherapy of genital warts
Yes 4 (4.1) 93
No 7 (4.0) 167 1.00
Electrosurgical treatment of genital warts
Yes 6 (6.5) 87
No 5 (2.8) 173 0.20
Loop electrosurgical excision procedure
Yes 5 (4.7) 101
No 6 (4.6) 159 0.76
Occupation
Physician 8 (5.3) 143
Non-physician 3 (2.5) 117 0.36
Work place
Dermato-venerology 6 (6.3) 90
Gynaecology 5 (2.9) 170 0.18
afisher’s exact test.
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infrequent associations between nasopharyngeal HPV 
prevalence and work exposure. Most HPV infections 
are transient and thus the prevalence deduced by point 
testing with swap and rinses are not able to measure 
the transmission rate over a period of years.
ACKNOWLEDGEMENTS
We thank Aline Marshall and the laboratory staff at Medical 
Microbiology, Malmö, for careful performance of the HPV 
analysis, Helle Wium Sørensen who provided excellent and 
enthusiastic assistance in planning sample collection and study 
logistics, and statistician Andreas Habicht, Significans Aps for 
data handling and analysis. 
Conflicts of interest. KK has received fees as a speaker and obtai-
ned research grants form Sanofi Pasteur MSD. CS has obtained 
research grants and received fees as a speaker and for Sanofi 
Pasteur MSD. KGM is the former managing director at Sanofi 
Pasteur MSD Denmark. The study was supported by a research 
grant from Sanofi Pasteur MSD, Denmark.
REfERENCES
1. Trottier H, franco EL. The epidemiology of genital human 
papillomavirus infection. Vaccine 2006; 24 Suppl 1: S1–15.
2. Nielsen A, Kjaer SK, Munk C, Iftner T. Type-specific HPV 
infection and multiple HPV types: prevalence and risk 
factor profile in nearly 12,000 younger and older Danish 
women. Sex Transm Dis 2008; 35: 276–282.
3. Skaaby S, Kofoed K. Anogenital warts in Danish men who 
have sex with men. Int J STD AIDS 2011; 22: 214–217.
4. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and 
management of non-cancerous HPV-related conditions: 
HPV-6/11 disease. Vaccine 2006; 24 Suppl 3: S3–35–S3/41.
5. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster 
W, Kurman RJ. Human papillomavirus infection of the 
cervix: relative risk associations of 15 common anogenital 
types. Obstet Gynecol 1992; 79: 328–337.
6. Garland SM, Steben M, Sings HL, James M, Lu S, Railkar 
R, et al. Natural history of genital warts: analysis of the pla-
cebo arm of 2 randomized phase III trials of a quadrivalent 
human papillomavirus (types 6, 11, 16, and 18) vaccine. J 
Infect Dis 2009; 199: 805–814.
7. Sturegard E, Johansson H, Ekstrom J, Hansson BG, Johns-
son A, Gustafsson E, et al. Human papillomavirus typing in 
reporting of condyloma. Sex Transm Dis 2013; 40: 123–129.
8. Gillison ML. Human papillomavirus-associated head and 
neck cancer is a distinct epidemiologic, clinical, and mo-
lecular entity. Semin Oncol 2004; 31: 744–754.
9. Schwartz SM, Daling JR, Doody DR, Wipf GC, Carter JJ, 
Madeleine MM, et al. Oral cancer risk in relation to sexual 
history and evidence of human papillomavirus infection. J 
Natl Cancer Inst 1998; 90: 1626–1636.
10. Mounts P, Shah KV, Kashima H. Viral etiology of juvenile- 
and adult-onset squamous papilloma of the larynx. Proc 
Natl Acad Sci U S A 1982; 79: 5425–5429.
11. Oriel JD. Natural history of genital warts. Br J Vener Dis 
1971; 47: 1–13.
12. Rintala M, Grenman S, Puranen M, Syrjanen S. Natural his-
tory of oral papillomavirus infections in spouses: a prospec-
tive finnish HPV family study. J Clin Virol 2006; 35: 89–94.
13. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, 
Kahle L, et al. Prevalence of oral HPV infection in the 
United States, 2009–2010. JAMA 2012; 307: 693–703.
14. ferenczy A, Bergeron C, Richart RM. Human papilloma-
virus DNA in CO2 laser-generated plume of smoke and 
its consequences to the surgeon. Obstet Gynecol 1990; 
75: 114–118.
15. Kashima HK, Kessis T, Mounts P, Shah K. Polymerase 
chain reaction identification of human papillomavirus DNA 
in CO2 laser plume from recurrent respiratory papillomato-
sis. Otolaryngol Head Neck Surg 1991; 104: 191–195.
16. Garden JM, O’Banion MK, Shelnitz LS, Pinski KS, Bakus 
AD, Reichmann ME, et al. Papillomavirus in the vapor of 
carbon dioxide laser-treated verrucae. JAMA 1988; 259: 
1199–1202.
17. Sood AK, Bahrani-Mostafavi Z, Stoerker J, Stone IK 
Human papillomavirus DNA in LEEP plume. Infect Dis 
Obstet Gynecol 1994; 2: 167–170.
18. Hallmo P, Naess O. Laryngeal papillomatosis with human 
papillomavirus DNA contracted by a laser surgeon. Eur 
Arch Otorhinolaryngol 1991; 248: 425–427.
19. Calero L, Brusis T. Larynxpapillomatose – erstmalige 
Anerkennung als Berufskrankheit bei einer OP-Schwester. 
Laryngorhinootologie 2003; 82: 790–793.
20. Weyandt GH, Tollmann f, Kristen P, Weissbrich B. Low 
risk of contamination with human papilloma virus during 
treatment of condylomata acuminata with multilayer argon 
plasma coagulation and CO(2) laser ablation. Arch Der-
matol Res 2011; 303: 141–144.
21. Ilmarinen T, Auvinen E, Hiltunen-Back E, Ranki A, Aalto-
nen LM, Pitkaranta A. Transmission of human papilloma-
virus DNA from patient to surgical masks, gloves and oral 
mucosa of medical personnel during treatment of laryngeal 
papillomas and genital warts. Eur Arch Otorhinolaryngol 
2012; 269: 2367–2371.
22. forslund O, Johansson H, Madsen GK, Kofoed K. The nasal 
mucosa contains a large spectrum of human papillomavirus 
types from the Betapapillomavirus and Gammapapilloma-
virus genera. J Infect Dis 2013; 208: 1335–1341. 
23. Söderlund-Strand A, Carlson J, Dillner J. Modified general 
primer PCR system for sensitive detection of multiple ty-
pes of oncogenic human papillomavirus. J Clin Microbiol 
2009; 47: 541–546.
24. Bellina JH, Stjernholm RL, Kurpel JE. Analysis of plume 
emissions after papovavirus irradiation with the carbon 
dioxide laser. J Reprod Med 1982; 27: 268–270.
25. Garden JM, O’Banion MK, Bakus AD, Olson C. Viral 
disease transmitted by laser-generated plume (aerosol). 
Arch Dermatol 2002; 138: 1303–1307.
26. forslund O, Johansson H, Madsen KG, Kofoed K. The nasal 
mucosa contains a large spectrum of human papillomavirus 
types from the betapapillomavirus and gammapapillomavi-
rus genera. J Infect Dis 2013; 208: 1335–1341.
27. Hansson BG, Rosenquist K, Antonsson A, Wennerberg J, 
Schildt EB, Bladstrom A, et al. Strong association between 
infection with human papillomavirus and oral and oro-
pharyngeal squamous cell carcinoma: a population-based 
case-control study in southern Sweden. Acta Otolaryngol 
2005; 125: 1337–1344.
28. Rautava J, Willberg J, Louvanto K, Wideman L, Syrjanen 
K, Grenman S, et al. Prevalence, genotype distribution and 
persistence of human papillomavirus in oral mucosa of wo-
men: a six-year follow-up study. PLoS One 2012; 7: e42171.
29. Gloster HM, Jr., Roenigk RK. Risk of acquiring human 
papillomavirus from the plume produced by the carbon 
dioxide laser in the treatment of warts. J Am Acad Dermatol 
1995; 32: 436–441.
30. Lobraico RV, Schifano MJ, Brader KR. Acquired HPV 
lesions compared in laser and nonlaser users. J Gynecol 
Surg 1989; 5: 77–85.
Acta Derm Venereol 95
